Event introduction slides by Thomas Brenzikofer. Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”. The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.

1. DayOne Core Team
Experts from across industry and stakeholders
Michael Rebhan, Novartis
Peter Groenen, Idorsia
Alain Bindels, Roche
Frank Kumli, Ernst & Young
Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics
Andreas Wicki, University Hospital Basel
Erik Schkommodau, University of Applied Science and Arts Northwestern Switzerland
Christian Bosshard, CSEM
Laurenz Baltzer, KARGER
Bram Stieltjes, University Hospital Basel
André Moeri, Medgate
Bhupinder Bhullar, Consultant
Douglas Haggstrom, Consultant
Thomas Brenzikofer, BaselArea.swiss
Fabian Streiff, Department of Economic, Social and Environmental Affairs of
the Canton of Basel-Stadt
DayOne Experts – 25.6.2019
DayOne Experts: next generation
clinical trials

2. Thomas Brenzikofer, BaselArea.swiss, Co-Founder DayOne
DayOne
Creating a world-leading hub for healthcare
innovation in precision medicine and digital health

3. the leading hub for healthcare innovation
in precision medicine

4. A growing community of healthcare innovators
1500 professionals, entrepreneurs, researchers across all disciplines

5. DayOne Core Team
Experts from across industry and stakeholders
Michael Rebhan, Novartis
Peter Groenen, Idorsia
Alain Bindels, Roche
Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics
Christian Elias Schneider, University of Basel
Andreas Wicki, Bram Stieltjes University Hospital Basel
Nicole Probst-Hensch, Melissa Penny, Swiss TPH
Erik Schkommodau, Enkelejda Miho, University of Applied Science and Arts FHNW
Christian Bosshard, CSEM
Laurenz Baltzer, KARGER
André Moeri, Medgate
Management Team:
Bhupinder Bhullar, Douglas Haggstrom, Viktor Bullain, Bejal Joshi, Consultants
Frank Kumli, Fabian Streiff, Thomas Brenzikofer, BaselArea.swiss

6. DayOne Partners
Public and Industry
INITIATED AND OPERATED BY
IN CLOSE COLLABORATION
WITH
KNOWLEDGE PARTNERS
SUPPORTING PARTNERS

7. DayOne
Mission
Create a world leading
hub for healthcare innovation,
built on the strength of the Basel region
respected for its impact
facilitating collaboration across disciplines and
industries with a focus on precision medicine
– the convergence of diagnostics, treatment and
digital health

8. Digitisation and Precision Medicine
Putting the Patient in the middle

9. The new paradigm
Patient centric innovation
initial failed
product
reservoir
redefined
patient
population
patient in
the middle
product
proposal
product
prototype
revised
product
repositioned
product
medicalneed
problem
statement
refined
product
proposal
product
experience
redefine
product
testinvent implement innovate
9

10. Implement
Innovate
Improve
Invent
Test
Collaboration is key
Neutral Plattform to explore ideas and setup projects
1
0

11. Implement
Innovate
Improve
Invent
Test
Innovation hub as a neutral Platform
Different activities reinforcing each other

12. DayOne Core Team
Experts from across industry and stakeholders
Michael Rebhan, Novartis
Peter Groenen, Idorsia
Alain Bindels, Roche
Frank Kumli, Ernst & Young
Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics
Andreas Wicki, University Hospital Basel
Erik Schkommodau, University of Applied Science and Arts Northwestern Switzerland
Christian Bosshard, CSEM
Laurenz Baltzer, KARGER
Bram Stieltjes, University Hospital Basel
André Moeri, Medgate
Bhupinder Bhullar, Consultant
Douglas Haggstrom, Consultant
Thomas Brenzikofer, BaselArea.swiss
Fabian Streiff, Department of Economic, Social and Environmental Affairs of
the Canton of Basel-Stadt
DayOne Experts – 25.6.2019
DayOne Experts: next generation
clinical trials

13. disrupting clinical trials
Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
Phase 1 Phase 2 Phase 3 Phase 4
20 – 80
participant
100 – 300
participant
1000 – 3000
participant
> 3000
participant
several month Up to 2 years Up to 4 years 1 year
safety efficacy
Safety, efficacy,
dosing
Longterm Effectiveness
+ cost effectiveness
33 percent
Success rate
70 percent
Success rate
25-30 percent
Success rate
70-90 percent
Success rate

14. faster patient recruitment
Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
Phase 1 Phase 2 Phase 3 Phase 4
20 – 80
participant
100 – 300
participant
1000 – 3000
participant
> 3000
participant
several month Up to 2 years Up to 4 years 1 year
safety efficacy
Safety, efficacy,
dosing
Longterm Effectiveness
+ cost effectiveness
33 percent
Success rate
70 percent
Success rate
25-30 percent
Success rate
70-90 percent
Success rate

15. self reporting
Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
Phase 1 Phase 2 Phase 3 Phase 4
20 – 80
participant
100 – 300
participant
1000 – 3000
participant
> 3000
participant
several month Up to 2 years Up to 4 years 1 year
safety efficacy
Safety, efficacy,
dosing
Longterm Effectiveness
+ cost effectiveness
33 percent
Success rate
70 percent
Success rate
25-30 percent
Success rate
70-90 percent
Success rate

16. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
Phase 1 Phase 2 Phase 3 Phase 4
20 – 80
participant
100 – 300
participant
1000 – 3000
participant
> 3000
participant
several month Up to 2 years Up to 4 years 1 year
safety efficacy
Safety, efficacy,
dosing
Longterm Effectiveness
+ cost effectiveness
33 percent
Success rate
70 percent
Success rate
25-30 percent
Success rate
70-90 percent
Success rate
more data

17. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
Phase 1 Phase 2 Phase 3 Phase 4
20 – 80
participant
100 – 300
participant
1000 – 3000
participant
> 3000
participant
several month Up to 2 years Up to 4 years 1 year
safety efficacy
Safety, efficacy,
dosing
Longterm Effectiveness
+ cost effectiveness
33 percent
Success rate
70 percent
Success rate
25-30 percent
Success rate
70-90 percent
Success rate
Better patient experience

18. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
complete new way…?

19. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
complete new way…?

20. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
complete new way…?

21. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/©
Time
open, virtual
trials
complete new way…?

22. 3 questions
how can we make clinical trials more efficient,
improve outcomes, providing better patient experience?
to what extend will the digital tools (re)open up
new fields of R&D?
will this lead to new ways of doing clinical research?

23. DayOne Core Team
Experts from across industry and stakeholders
Michael Rebhan, Novartis
Peter Groenen, Idorsia
Alain Bindels, Roche
Frank Kumli, Ernst & Young
Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics
Andreas Wicki, University Hospital Basel
Erik Schkommodau, University of Applied Science and Arts Northwestern Switzerland
Christian Bosshard, CSEM
Laurenz Baltzer, KARGER
Bram Stieltjes, University Hospital Basel
André Moeri, Medgate
Bhupinder Bhullar, Consultant
Douglas Haggstrom, Consultant
Thomas Brenzikofer, BaselArea.swiss
Fabian Streiff, Department of Economic, Social and Environmental Affairs of
the Canton of Basel-Stadt
18:45
Welcome and introduction: Thomas Brenzkofer
19:00
Input Speeches and Panel Discussion
Stijn Rogiers, SAS
Lars G. Hemkens, University Hospital Basel
Tomasz Sablinski, Transparency Life Sciences
Catherine Wu, Roche
Randy Ramin-Wright, Clinerion
20:30
closing remarks followed by networking apero

24. Next Events – save the dates!
dayOne acceleration – 31. July
dayOne conference – 9. September
new approaches in patient centricity – 30. October
future business models – 3. December

25. thomas.brenzikofer@baselarea.swiss
CONTACT
the leading hub for healthcare innovation
in precision medicine

26. www.dayone.swiss
#dayonebasel
LinkedIn Groups:
„DayOne – Innovation Hub
for Precision Medicine“